Industry Growth Insights published a new data on “Lung Cancer Diagnostics Market”. The research report is titled “Lung Cancer Diagnostics Market research by Types (Immunoassays, Flow Cytometry, Rapid Tests, Molecular Assays, Tissue Arrays, Circulating Tumor Cells, Pharmacodiagnostics, Biomarkers, Other), By Applications (Industrial, Healthcare, Other), By Players/Companies Roche Diagnostics, BioMérieux, Qiagen, Advpharma, AIT Austrian Institute of Technology, Courtagen Life Sciences, DiagnoCure, BioMark Diagnostics, Mayo Clinic, HalioDx SAS”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Lung Cancer Diagnostics Market Research Report
By Type
Immunoassays, Flow Cytometry, Rapid Tests, Molecular Assays, Tissue Arrays, Circulating Tumor Cells, Pharmacodiagnostics, Biomarkers, Other
By Application
Industrial, Healthcare, Other
By Companies
Roche Diagnostics, BioMérieux, Qiagen, Advpharma, AIT Austrian Institute of Technology, Courtagen Life Sciences, DiagnoCure, BioMark Diagnostics, Mayo Clinic, HalioDx SAS
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
150
Number of Tables & Figures
105
Customization Available
Yes, the report can be customized as per your need.
Global Lung Cancer Diagnostics Market Report Segments:
The global Lung Cancer Diagnostics market is segmented on the basis of:
Types
Immunoassays, Flow Cytometry, Rapid Tests, Molecular Assays, Tissue Arrays, Circulating Tumor Cells, Pharmacodiagnostics, Biomarkers, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Industrial, Healthcare, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche Diagnostics
- BioMérieux
- Qiagen
- Advpharma
- AIT Austrian Institute of Technology
- Courtagen Life Sciences
- DiagnoCure
- BioMark Diagnostics
- Mayo Clinic
- HalioDx SAS
Highlights of The Lung Cancer Diagnostics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Immunoassays
- Flow Cytometry
- Rapid Tests
- Molecular Assays
- Tissue Arrays
- Circulating Tumor Cells
- Pharmacodiagnostics
- Biomarkers
- Other
- By Application:
- Industrial
- Healthcare
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lung Cancer Diagnostics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lung cancer diagnostics is the process of detecting lung cancer in its early stages. Early detection can improve the chances for successful treatment.
Some of the key players operating in the lung cancer diagnostics market are Roche Diagnostics, BioMƒÂ©rieux, Qiagen, Advpharma, AIT Austrian Institute of Technology, Courtagen Life Sciences, DiagnoCure, BioMark Diagnostics, Mayo Clinic, HalioDx SAS.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Lung Cancer Diagnostics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Lung Cancer Diagnostics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Lung Cancer Diagnostics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Lung Cancer Diagnostics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Lung Cancer Diagnostics Market Size & Forecast, 2018-2028
4.5.1 Lung Cancer Diagnostics Market Size and Y-o-Y Growth
4.5.2 Lung Cancer Diagnostics Market Absolute $ Opportunity
Chapter 5 Global Lung Cancer Diagnostics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Lung Cancer Diagnostics Market Size Forecast by Type
5.2.1 Immunoassays
5.2.2 Flow Cytometry
5.2.3 Rapid Tests
5.2.4 Molecular Assays
5.2.5 Tissue Arrays
5.2.6 Circulating Tumor Cells
5.2.7 Pharmacodiagnostics
5.2.8 Biomarkers
5.2.9 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Lung Cancer Diagnostics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Lung Cancer Diagnostics Market Size Forecast by Applications
6.2.1 Industrial
6.2.2 Healthcare
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Lung Cancer Diagnostics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Lung Cancer Diagnostics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Lung Cancer Diagnostics Analysis and Forecast
9.1 Introduction
9.2 North America Lung Cancer Diagnostics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Lung Cancer Diagnostics Market Size Forecast by Type
9.6.1 Immunoassays
9.6.2 Flow Cytometry
9.6.3 Rapid Tests
9.6.4 Molecular Assays
9.6.5 Tissue Arrays
9.6.6 Circulating Tumor Cells
9.6.7 Pharmacodiagnostics
9.6.8 Biomarkers
9.6.9 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Lung Cancer Diagnostics Market Size Forecast by Applications
9.10.1 Industrial
9.10.2 Healthcare
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Lung Cancer Diagnostics Analysis and Forecast
10.1 Introduction
10.2 Europe Lung Cancer Diagnostics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Lung Cancer Diagnostics Market Size Forecast by Type
10.6.1 Immunoassays
10.6.2 Flow Cytometry
10.6.3 Rapid Tests
10.6.4 Molecular Assays
10.6.5 Tissue Arrays
10.6.6 Circulating Tumor Cells
10.6.7 Pharmacodiagnostics
10.6.8 Biomarkers
10.6.9 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Lung Cancer Diagnostics Market Size Forecast by Applications
10.10.1 Industrial
10.10.2 Healthcare
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Lung Cancer Diagnostics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Lung Cancer Diagnostics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Lung Cancer Diagnostics Market Size Forecast by Type
11.6.1 Immunoassays
11.6.2 Flow Cytometry
11.6.3 Rapid Tests
11.6.4 Molecular Assays
11.6.5 Tissue Arrays
11.6.6 Circulating Tumor Cells
11.6.7 Pharmacodiagnostics
11.6.8 Biomarkers
11.6.9 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Lung Cancer Diagnostics Market Size Forecast by Applications
11.10.1 Industrial
11.10.2 Healthcare
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Lung Cancer Diagnostics Analysis and Forecast
12.1 Introduction
12.2 Latin America Lung Cancer Diagnostics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Lung Cancer Diagnostics Market Size Forecast by Type
12.6.1 Immunoassays
12.6.2 Flow Cytometry
12.6.3 Rapid Tests
12.6.4 Molecular Assays
12.6.5 Tissue Arrays
12.6.6 Circulating Tumor Cells
12.6.7 Pharmacodiagnostics
12.6.8 Biomarkers
12.6.9 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Lung Cancer Diagnostics Market Size Forecast by Applications
12.10.1 Industrial
12.10.2 Healthcare
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Lung Cancer Diagnostics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Lung Cancer Diagnostics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Lung Cancer Diagnostics Market Size Forecast by Type
13.6.1 Immunoassays
13.6.2 Flow Cytometry
13.6.3 Rapid Tests
13.6.4 Molecular Assays
13.6.5 Tissue Arrays
13.6.6 Circulating Tumor Cells
13.6.7 Pharmacodiagnostics
13.6.8 Biomarkers
13.6.9 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Lung Cancer Diagnostics Market Size Forecast by Applications
13.10.1 Industrial
13.10.2 Healthcare
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Lung Cancer Diagnostics Market: Competitive Dashboard
14.2 Global Lung Cancer Diagnostics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche Diagnostics
14.3.2 BioMérieux
14.3.3 Qiagen
14.3.4 Advpharma
14.3.5 AIT Austrian Institute of Technology
14.3.6 Courtagen Life Sciences
14.3.7 DiagnoCure
14.3.8 BioMark Diagnostics
14.3.9 Mayo Clinic
14.3.10 HalioDx SAS
